POTENTIATION OF ANTIBIOTIC EFFECT
The present invention relates to compositions, kits and methods using combinations of surfactants or cell wall-hydrolyzing enzymes with antibiotics to potentiate the antibiotic effect against bacterial infections. In some embodiments, the surfactant is a pore-forming biosurfactant such as rhamnolipids and the antibiotic is an aminoglycoside antibiotic such as tobramycin.
1 . A composition comprising a surfactant and an aminoglycoside antibiotic.
2 . The composition of claim 1 , wherein the surfactant is a pore-forming biosurfactant.
3 . The composition of claim 2 , wherein the pore-forming biosurfaetant is a rhamnolipid.
4 . The composition of claim 3 , wherein the rhamnolipid is from Pseudomonas aeruginosa.
5 . The composition of claim 3 , wherein the rhamnolipid is a mono-rhamnolipid, a di-rhamnolipid, or a combination thereof.
6 . The composition of claim 2 , wherein the pore-forming biosurfactant is a xylolipid.
7 . The composition of claim 1 , wherein the surfactant and the aminoglycoside antibiotic are present in synergistic amounts.
8 . The composition of claim 1 , wherein the aminoglycoside antibiotic is selected from the group consisting of streptomycin, kanamycin A, amikacin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin, neomycin B, neomycin C, and neomycin E (paromornycin).
9 . The composition of claim 8 , wherein the aminoglycoside antibiotic is tobramycin.
10 . A kit comprising a surfactant and an aminoglyeoside antibiotic.
11 - 21 . (canceled)
22 . A method of treating a bacterial infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a surfactant and an aminoglycoside antibiotic, wherein the bacterial infection, is treated.
23 - 24 . (canceled)
25 . The method of claim 21 , wherein the bacteria is antibiotic resistant or antibiotic tolerant.
26 . The method of claim 21 , wherein the surfactant decreases the minimum inhibitory concentration of the aminoglycoside antibiotic.
27 . The method of claim 21 , wherein the bacteria is a gram-negative bacteria.
28 . The method of claim 21 , wherein the bacteria is a gram-positive bacteria.
29 . The method of claim 28 , wherein the bacteria is Staphylococcus aureus.
30 . The method of claim 29 , wherein the bacteria is methicillin-resistant Staphylococcus aureus.
31 - 32 . (canceled)
33 . The method of claim 21 , wherein the surfactant and the aminoglycoside antibiotic are administered in synergistic amounts.
34 . The method of claim 21 , wherein the aminoglycoside antibiotic is selected from the group consisting of streptomycin, kanamycin A, amikacin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin, neomycin. B, neomycin C, and neomycin (paromornycin).
35 . (canceled)
36 . The method of claim 21 , wherein he surfactant is a pore-forming biosurfactant,
37 - 40 . (canceled)